Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STROKER: SBRT + Systemic Therapy vs Systemic Therapy Alone in Oligometastatic Kidney Cancer
NCT06726421Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2024
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival up to 5 years. Started Sep 2024; status: recruiting.
02
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06726421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726421.